What is Figur8?
Figur8 is a pioneering force in the musculoskeletal (MSK) health sector, leveraging advanced sensor technology and artificial intelligence to redefine patient care. At the core of its operations is the FDA-registered bioMotion Assessment Platform (bMAP), which delivers lab-grade biomechanics data to clinicians and healthcare providers. By digitizing the assessment process, Figur8 enables more precise diagnostics and personalized treatment pathways, effectively moving the industry away from subjective reporting toward objective, data-driven recovery monitoring. The platform serves a diverse ecosystem, including healthcare providers, payers, and patients, aiming to optimize risk evaluation and streamline the often-complex claims management process in MSK health. Through its commitment to clinical training and technological integration, Figur8 is establishing a new standard for efficiency and efficacy in physical medicine.
How much funding has Figur8 raised?
Figur8 has raised a total of $25M across 1 funding round:
Series A
$25M
Series A (2023): $25M with participation from First Spark Ventures, DigiTx Partners, and Phoenix Venture Partners
Key Investors in Figur8
First Spark Ventures
First Spark Ventures is a Deep Tech venture capital fund that invests in breakthrough technologies aimed at enhancing health, safety, and productivity, with a focus on Digital Biology and CyberPhysical Systems.
DigiTx Partners
DigiTx Partners is a venture capital firm that focuses on investing in early-stage companies within the digital health sector, emphasizing personalized medicine and data analytics to enhance patient outcomes.
Phoenix Venture Partners
PVP is a venture capital firm that specializes in transforming innovative technologies into market-ready products, focusing on advanced materials, novel devices, and life sciences.
What's next for Figur8?
With this major enterprise-level funding, Figur8 is poised to scale its operations and expand the reach of its bMAP platform across broader healthcare networks. The strategic focus will likely center on deepening the integration of its AI-driven analytics into existing clinical workflows, thereby enhancing the scalability of its diagnostic tools. As the company matures, the emphasis will shift toward strengthening partnerships with large-scale payers and health systems to demonstrate long-term cost savings and improved patient outcomes. By leveraging its recent capital injection, Figur8 is set to solidify its market position as a leader in the digital transformation of musculoskeletal health, potentially setting the stage for future expansion into new therapeutic areas or international markets where objective biomechanical assessment is increasingly in demand.
See full Figur8 company page
